New Strategies in the World of Anticoagulant Therapy. October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center
|
|
- Dortha Watts
- 5 years ago
- Views:
Transcription
1 New Strategies in the World of Anticoagulant Therapy October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center
2 Presenter Disclosure Information Elaine M. Hylek, MD, MPH Research: NIH/NINDS, NIH/NHLBI Bristol-Myers Squibb-Executive Steering Committee ARISTOTLE trial, Ortho-McNeil-Executive Steering Committee ORBIT-AF Registry Advisory Boards: Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Pfizer UNLABELED/UNAPPROVED USES DISCLOSURE: This presentation discusses the unapproved use of apixaban for stroke prevention in atrial fibrillation.
3 Projected number of persons with AF in the U.S. between 2000 and 2050 Assumes no further increase in age-adjusted AF incidence (solid curve) and assumes a continued increase in incidence rate as evident in 1980 to 2000 (dotted curve) Miyasaka, Y. et al. Circulation 2006;114:
4 TEE depicting a large LAA thrombus attached to the lateral wall Hesse, B. et al. Circulation 2006;113:e e
5 Efficacy of Warfarin in Atrial Fibrillation Five Randomized Trials in Non-Rheumatic AF Study Warfarin (#) Cont. (#) INR RR p-value AFASAK % SPAF % 0.01 BAATAF % <0.05 CAFA* % 0.25 SPINAF % *Stopped early due to published positive results 66% overall risk reduction for stroke
6 HAZARDS OF WARFARIN Budnitz D, et al. NEJM 2012
7 HAZARDS OF WARFARIN Budnitz D, et al. NEJM 2012
8 Warfarin dosing is complex Factors that correlate with warfarin dose Age Body surface area or weight Amiodarone Other drugs (e.g. acetaminophen) Race Sex Plasma vitamin K level Decompensated CHF Active malignancy Genetic status CYP2C9 (up to 15%) VKORC1 (up to 25%) Age, sex, weight (10 20%) Other factors (up to 40%) CHF = congestive heart failure; CYP2C9 = cytochrome P450 2C9; INR = international normalized ratio; VKORC1 = vitamin K epoxide reductase complex subunit 1
9 Hylek, EM. J Cardiovasc Med 2009;10:605-09
10 INTRACRANIAL HEMORRHAGE ON WARFARIN OR 80 years of age 2.8 (1.3 to 5.8) p< /3 occur with an INR in range 46% mortality 17% major deficit Hylek EM, Singer DE. Ann Intern Med 1994
11 Transitions and Fragmentation of Care 86 year old male admitted to hospital with decompensated heart failure. Maintenance weekly warfarin dose prior to admission: 50 mg: 5 mg tablet: 1 ½ tablets per day M-Sat M and 1 tablet on Sun. Discharged on 7.5 mg tablet. Patient continued to take 1 ½ tablets per day. Readmitted with INR=9.2
12 Optimizing Benefit and Reducing Risk Hemorrhage Thrombosis
13 Novel Anticoagulants TF/VIIa X IX Rivaroxaban Apixaban Edoxaban IXa VIIIa Xa Va II Dabigatran IIa Fibrinogen Fibrin Adapted from Turpie and Weitz & Bates, J Thromb Haemost 2007
14 RE-LY study design open-label Atrial fibrillation with 1 risk factor Absence of contraindications R Warfarin 1 mg, 3 mg, 5 mg (INR ) N=6000 Dabigatran etexilate 110 mg bid N=6000 Dabigatran etexilate 150 mg bid N=6000 Primary objective: To establish the non-inferiority of dabigatran etexilate to warfarin Ezekowitz MD, et al. Am Heart J 2009;157: Connolly SJ., et al. NEJM published online on Aug 30th DOI /NEJMoa
15 RE-LY Time to first stroke / SEE 0.05 RR 0.91 (95% CI: ) p<0.001 (noninferiority) p=0.34 (superiority) Cumulative hazard rates Warfarin Dabigatran etexilate 110 mg Dabigatran etexilate 150 mg 1.69% 1.53% 1.11% RRR 34% RR 0.66 (95% CI: ) p<0.001 (noninferiority) p<0.001 (superiority) Years Connolly SJ., et al. NEJM Aug 30th DOI /NEJMoa
16 Hemorrhagic stroke 50 RR 0.31 (95% CI: ) p<0.001 (sup) RR 0.26 (95% CI: ) p<0.001 (sup) Number of events % RRR 69% % RRR 74% % D110 mg BID D150 mg BID Warfarin 6,015 6,076 6,022 Connolly SJ., et al. NEJM published online on Aug 30th DOI /NEJMoa
17 Incidence of Major Hemorrhage Dabigatran vs Warfarin (RE-LY) Rate RR P Dabigatran 150 mg BID 3.11% Warfarin 3.36% (superiority) More GI bleeds with 150 mg dose compared to warfarin.
18 Discontinuations and Adverse Effects Dabigatran 110 Dabigatran 150 Warfarin DYSPEPSIA 11.8%* 11.3%* 5.8% *p<0.001 MYOCARDIAL 0.82% 0.81% 0.64% INFARCTION
19 Dabigatran Trials Meta-analysis: Mortality Uchino, K. et al. Arch Intern Med 2012;0:archinternmed v1-6.
20 ROCKET AF Protocol Schema Atrial Fibrillation Rivaroxaban 20 mg daily 15 mg for Cr Cl Randomize Double blind / Double Dummy (n ~ 14,000) Warfarin INR target ( inclusive) At least 2 of: CHF Hypertension Age 75 Diabetes AND/OR Stroke, TIA or Systemic Embolus Monthly Monitoring and adherence to standard of care guidelines Primary Endpoint: Stroke or non-cns Systemic Embolism Statistics: non-inferiority, >95% power, 2.3% warfarin event rate From Califf, DCRI
21 ROCKET-AF Primary Efficacy Outcome Stroke and non-cns Embolism On Treatment N= 14,143 Rivaroxaban Event Rate Warfarin Event Rate HR (95% CI) 0.79 (0.65,0.95) P-value ITT N= 14, (0.74,1.03) Rivaroxaban better Warfarin better Event Rates are per 100 patient-years Based on Safety on Treatment or Intention-to-Treat thru Site Notification populations
22 Key Secondary Efficacy Outcomes Rivaroxaban Warfarin Event Rate Event Rate HR (95% CI) P-value Vascular Death, Stroke, Embolism (0.74, 0.99) Stroke Type Hemorrhagic (0.37, 0.93) Ischemic (0.75, 1.17) Unknown Type (0.25, 1.67) Non-CNS Embolism (0.09, 0.61) Myocardial Infarction (0.63, 1.06) All Cause Mortality (0.70, 1.02) Vascular (0.73, 1.10) Non-vascular (0.36, 1.08) Unknown Cause (0.40, 1.41) 0.370
23 Primary Safety Outcomes Rivaroxaban Warfarin Event Rate or N (Rate) Event Rate or N (Rate) HR (95% CI) P-value Major (0.90, 1.20) >2 g/dl Hgb drop (1.03, 1.44) Transfusion (> 2 units) (1.01, 1.55) Critical organ bleeding (0.53, 0.91) Bleeding causing death (0.31, 0.79) Intracranial Hemorrhage 55 (0.49) 84 (0.74) 0.67 (0.47, 0.94) Intraparenchymal 37 (0.33) 56 (0.49) 0.67 (0.44, 1.02) Intraventricular 2 (0.02) 4 (0.04) Subdural 14 (0.13) 27 (0.27) 0.53 (0.28, 1.00) Subarachnoid 4 (0.04) 1 (0.01) Event Rates are per 100 patient-years Based on Safety on Treatment Population
24 Atrial Fibrillation with at Least One Additional Risk Factor for Stroke Inclusion risk factors Age 75 years Prior stroke, TIA, or SE HF or LVEF 40% Diabetes mellitus Hypertension Randomize double blind, double dummy (n = 18,201) Major exclusion criteria Mechanical prosthetic valve Severe renal insufficiency Need for aspirin plus thienopyridine Apixaban 5 mg oral twice daily (2.5 mg BID in selected patients) Warfarin (target INR 2-3) 2 Warfarin/warfarin placebo adjusted by INR/sham INR based on encrypted point-of-care testing device Primary outcome: stroke or systemic embolism Hierarchical testing: non-inferiority for primary outcome, superiority for primary outcome, major bleeding, death
25 Primary Outcome Stroke (ischemic or hemorrhagic) or systemic embolism P (non-inferiority)< % RRR Apixaban 212 patients, 1.27% per year Warfarin 265 patients, 1.60% per year HR 0.79 (95% CI, ); P (superiority)=0.011 No. at Risk Apixaban Warfarin
26 Efficacy Outcomes Outcome Apixaban (N=9120) Event Rate (%/yr) Warfarin (N=9081) Event Rate (%/yr) HR (95% CI) P Value Stroke or systemic embolism* (0.66, 0.95) Stroke (0.65, 0.95) Ischemic or uncertain (0.74, 1.13) 0.42 Hemorrhagic (0.35, 0.75) <0.001 Systemic embolism (SE) (0.44, 1.75) 0.70 All-cause death* (0.80, 0.998) Stroke, SE, or all-cause death (0.81, 0.98) Myocardial infarction (0.66, 1.17) 0.37 * Part of sequential testing sequence preserving the overall type I error
27 Bleeding Outcomes Outcome Primary safety outcome: ISTH major bleeding* Apixaban (N=9088) Event Rate (%/yr) Warfarin (N=9052) Event Rate (%/yr) HR (95% CI) P Value (0.60, 0.80) <0.001 Intracranial (0.30, 0.58) <0.001 Gastrointestinal (0.70, 1.15) 0.37 Major or clinically relevant non-major bleeding (0.61, 0.75) <0.001 GUSTO severe bleeding (0.35, 0.60) <0.001 TIMI major bleeding (0.46, 0.70) <0.001 Any bleeding (0.68, 0.75) <0.001 * Part of sequential testing sequence preserving the overall type I error
28 New Oral Anticoagulants: Summary Property Dabigatran Rivaroxaban Apixaban Edoxaban Route of admin Oral Oral Oral Oral Target Thrombin FXa FXa FXa Dosing Twice daily Once daily Twice daily Once daily Monitoring required No No No No Half-life life (hrs) Mode of elimination Renal 80% Renal ~ 36% Renal ~ 25% Renal ~ 35%
29 Practical Considerations Translation across indication Atrial fibrillation and valvular heart disease Atrial fibrillation and ACS Atrial fibrillation and DVT or PE Reversibility-trauma, hemorrhage, surgery Select situations in which monitoring would be desirable Renal function PGP and CYP interactions
30 Case
31 Gender: Age: Indication for OAC: Associated diseases: Medications: Habits: Male 73 years old Paroxysmal non-valvular AF Hypertension, peripheral arterial disease, chronic kidney disease Stage III, GFR 48 ACEI, metoprolol, hydrochlorothiazide, atorvastatin Smoker, very active lifestyle, doesn t like doctors or taking medications
32 Camm AJ et al. Eur Heart J 2010;31: CHA 2 DS 2 VASc score= 3
33 Self monitors warfarin. He is not interested in switching to a new oral anticoagulant. He thinks he is doing fine with self management. Average INR monitoring frequency: Weekly Average TTR: 62% Previous major bleeding: Diverticular bleed 5 years ago
34 2011 ACCF/AHA/HRS Focused Update Selection of patients with AF and 1 risk factor for stroke who could benefit from treatment with dabigatran as opposed to warfarin should consider individual clinical features, including the ability to comply with twice-daily dosing, availability of an anticoagulation management program, patient preferences, cost, and other factors Because of the twice-daily dosing and greater risk of non-hemorrhagic side effects with dabigatran, patients already taking warfarin with excellent INR control may have little to gain by switching to dabigatran. Wann LS, et al. Heart Rhythm March 2011
35 Effect of TTR on Primary Endpoints In RELY Wallentin, et al. Lancet 2010
36 He presents to your office with symptoms concerning for TIA. Sudden onset of right-sided visual disturbance 10 days ago. Thinks the symptoms lasted 20 minutes. When his vision spontaneously recovered, he decided to wait to seek medical advice. VS: BP=138/72, HR=70 Cardiac: RRR, S1S2 no m/r/g Vascular: carotids 2+ no bruits Neuro exam: CN intact, motor 5/5 all muscle groups, no sensory deficit, cerebellar testing intact INR today: 2.1
37 What would you do now? 1. Continue warfarin with INR target range Add ASA 81mg and continue warfarin INR range Switch to dabigatran 150 mg twice daily 4. Switch to rivaroxaban 20 mg per day 5. Switch to rivaroxaban 15 mg per day
38 AGE RENAL FUNCTION BLEEDING HISTORY ADHERENCE COST PATIENT PREFERENCE
39 RE-LY: Prior stroke subgroup analysis - stroke or systemic embolism Warfarin D 110 mg BID D 150 mg BID Overall study population Annual rate (%) RR vs. warfarin P value 0.34 <0.001 Prior stroke/tia Annual rate (%) RR vs. warfarin P value Diener HC et al. ISC 2010; abstr 195
40 RE-LY: Prior stroke subgroup analysis - haemorrhagic stroke Warfarin D 110 mg BID D 150 mg BID Overall study population Annual rate (%) RR vs warfarin P value <0.001 <0.001 Prior stroke/tia Annual rate (%) RR vs. warfarin P value Diener HC et al. ISC 2010; abstr 195
41 How would you perform the transition after stopping warfarin? 1. Start dabigatran the same day 2. Start dabigatran after 48 hrs 3. Check INR after 48 hrs and start dabigatran when INR < Start rivaroxaban when INR < 3.0
42 Stroke/systemic embolism: no Bleeding: no Compliance: Side effect: full no He states he doesn t like the new medication. Wants to go back to warfarin. He feels more secure knowing how thin his blood is with selftesting.
43 If you decide to switch back to warfarin, would you: 1. Stop rivaroxaban and start warfarin the same day with his previous maintenance dose 2. Transition to LMWH and overlap with warfarin until INR > Continue rivaroxaban while initiating warfarin, overlap treatment for 2-3 days. CAUTION re: reliance on INR in this setting.
44 Gender: Female Age: 74 years old Indication for OAC: Paroxysmal non-valvular AF Associated diseases: Medications: Hypertension, peripheral arterial disease, chronic kidney disease Stage III, GFR 40, osteoarthritis ACEI, metoprolol, hydrochlorothiazide, atorvastatin, occasional NSAID
45 Hylek, EM. J Cardiovasc Med 2009;10:605-09
46 Gallagher AM et al. Thromb Haemost 2011;106:968-77
47 Patients on warfarin with: TTR < 50-55% Grade of recommendation A history of cerebral bleeding A time-demanding work schedule/important logistic problems - concomitant treatment with interfering drugs (INR fluctuations) - strong wish to take new OAC/unwillingness to frequent blood testing - Pengo V et al. Thromb Haemost 2011:106:868-76
48 The HAS BLED score is: whereby a score of 3 indicates high risk, and some caution and regular review of the patient is needed following the initiation of antithrombotic therapy, Camm AJ et al. Eur Heart J 2010;31:
49 HAS BLED score performed better than the HEMORR2HAGES and ATRIA scores, as reflected by ROC analysis, reclassification analysis, and decision curve analysis. HAS BLED was the only score that demonstrated a significant predictive performance for intracranial hemorrhage (c index: 0.75; p=0.03). An ATRIA score>3 was not significantly associated with the risk for any clinically relevant bleeding on Cox regression or on ROC analysis (c index: 0.50; p=0.87).
50 Polypharmacy and Non-adherence Strongest predictor of non-adherence is the # of medications Non-adherence rates estimated 25-50% Intentional about 75% of the time Changes in regimen made by patients to: -increase convenience -reduce adverse effects or -decrease refill expense
51 Medication Adherence by Dose Frequency (systematic review: 76 studies ) AJ Claxton et al. Clinical Therapeutics :
52 What agent would you choose for this patient? 1. Dabigatran 150 mg BID 2. Dabigatran 75 mg BID 3. Rivaroxaban 20 mg QD 4. Rivaroxaban 15 mg QD 5. Continue warfarin with closer follow-up; engage family in care
53 Presents to emergency department with complaints of dizziness. States hasn t felt well, arthritis giving her problems. Increased NSAIDS. Also notes decreased oral intake due to summer heat. Hasn t missed any medications after extended office discussion 3 months ago. VS: BP=102/62, HR=120, appears volume depleted Lungs-clear Cardiac: Tachy, S1S2 no m/r/g Abd: soft, mild tenderness midepigastric area Rectal: FOB+, melena Hemoglobin: egfr: 7.6 mg/dl 24 ml/min
54 Pharmacokinetics with Varying Levels of Renal Dysfunction Elimination half life with CrCl > 80 ml/min Elimination half life with CrCl ml/min Elimination half life with CrCl ml/min Elimination half life with CrCl < 30 ml/min Apixaban Dabigatran Rivaroxaban 15.1 hr 13.8 hr 8.3 hr 14.6 hr 16.6 hr 8.7 hr 17.6 hr 18.7 hr 9.0 hr 17.3 hr 27.5 hr 9.5 hr Kaatz S, et al. Am J Hematol May;87 Suppl 1:S PMID:
55 Guide to the Management of Bleeding in Patients Taking NOAC Patients with bleeding on NOAC therapy Mild bleeding Moderate-Severe bleeding Life-threatening bleeding Delay next dose or discontinue treatment as appropriate Mechanical compression Surgical intervention Fluid replacement and hemodynamic support Blood product transfusion Oral charcoal Hemodialysis? Prothrombin Complex Concentrate? (Circulation 2011;124:1573-9) Consideration of rfviia or PCC Charcoal filtration? Prothrombin Complex Concentrate (Circulation 2011;124:1573-9) Hankey GJ and Eikelboom JW. Circulation. 2011; 123:
56 Novel anticoagulants may be safer in the elderly population due to their wider therapeutic index, shorter t 1/2, lack of dietary interference, and fewer drug interactions. Older individuals with AF are at the highest risk of stroke, the highest risk of hemorrhage, and the highest risk of stopping therapy. Further research is needed to inform commonly encountered clinical situations to optimize the effectiveness of these novel agents in routine practice.
Thrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationKenneth W. Mahaffey, MD and Keith AA Fox, MB ChB
Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationNew oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials
New oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials Dimitri Richter, MD, FESC, FAHA Head of Cardiac Dept., Athens Euroclinic General Secretary of Hellenic Lipidology Society Member
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationWarfarin Management-Review
Warfarin Management-Review December 18, 2012 Elaine M. Hylek, MD, MPH Director, Thrombosis Clinic and Anticoagulation Service Boston University Medical Center Areas for Discussion Implications of time
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationDisclosures. Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation
12:45 1:45 pm Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation SPEAKER Christian Ruff, MD, MPH Presenter Disclosure Information
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationNew drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle
New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle CONCLUSIONS 1. Arrival of new anticoagulants is a Good Thing. CONCLUSIONS 1. Arrival of new anticoagulants
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationPharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO
Pharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Disclosures None Risk of
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationEdoxaban: The newest NOAC option for stroke prevention in AF
Edoxaban: The newest NOAC option for stroke prevention in AF Dr. Paul Angaran, MD FRCPC Cardiac Electrophysiologist St. Michael s Hospital, Toronto February 11, 2017 Disclosures Relationships with commercial
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationAnticoagulation: A Changing Landscape. Kelly Matsuda Pharm.D. July 16, Kelly Matsuda Pharm.D. July 16, 2011
Anticoagulation: A Changing Landscape Kelly Matsuda Pharm.D. July 16, 2011 Kelly Matsuda Pharm.D. July 16, 2011 Objectives Review epidemiology of stroke/tia and atrial fibrillation. Review of warfarin
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationConflict of interest statement
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial J.J.V. McMurray 1, B. Lewis
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationNOACs in AF. Dr Fiona Stewart. Auckland Heart Group and Auckland DHB
NOACs in AF Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACS for AF True/False All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF NOACS are more effective than warfarin
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationNadine Ajzenberg** Marie-Genevieve Huisse** Isabelle Mahé*** Edith Peynaud **** Aurelie Roche* Patricia Esselin* Laurence Auguste-Charlery*
«new oral anticoagulants and brain specificity» Claire Bal dit Sollier * Ariane Davout * Sun-Young Park* Irène Clavijo* Adeline-Zoe Thoux * Ioana Muller* Ludovic Drouet* Nadine Ajzenberg** Marie-Genevieve
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationDigoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD, PhD, FACC on behalf of the ARISTOTLE Investigators
More informationΑντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationModeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD
Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD Mount Sinai School of Medicine New York, NY Session II. Weighing the Risks and Benefits
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Risk Stratification in Antithrombotic Management: Is There Room for Improvement? August 28, 2011 Elaine M. Hylek, MD, MPH Boston University DISCLOSURE INFORMATION Research:
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationDavid Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More information